cyrilzakka/clinical-trials huggingface dataset:
Postpartum Uterotonic Administration

The investigators are planning to determine the effect of the timing of oxytocin administration on the amount of blood loss, necessity for additional medical or surgical interventions.

The investigators are studying the effects of the timing of intramuscular oxytocin administration in the third stage of labour. The investigators are measuring the postpartum blood loss: quantitatively in the postpartum 1st hour and indirectly by the decrease in the hemoglobin-haematocrit levels in the postpartum 24th hour. The investigators are monitoring the length of the third stage of labour, and the need for extra uterotonics and/or surgical interventions.

Eligibility Criteria:
Inclusion Criteria:

* Cephalic presentation
* Singleton pregnancy
* Gestational age \>35 weeks,
* In active labour.
* Expected fetal birth weight 2500-4500 grams.

Exclusion Criteria:

* Acute Fetal Distress
* Conversion to abdominal delivery
* Persistent high blood pressure (\>140/90mmHg)
* Placenta Previa
* Ablatio placenta
* Previous C-Section
* Uterine scar
* Postpartum hemorrhage in previous pregnancies.
* Hydramnios
* Maternal infection
* Forceps/Vacuum Assisted deliveries
* Abnormal placentation ( Placenta accreta, increta or percreta)
* Coagulation Defects
* Hemoglobin \< 8g/dl
Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record

The purpose of the study is to measure the effectiveness of a social marketing-based medical education intervention on student use of evidence-based templates for documenting outpatient asthma care within an electronic medical record.

The purpose of the study was to measure the effectiveness of a physician-educator led clinical documentation workshop, embedded with 7 persuasive social-marketing based messages, on medical student response using a targeted asthma template. Stated differently, whether a physician-educator could "persuade" medical students to use an evidence-based EMR asthma template to document an outpatient mild persistent asthma encounter with a patient.

Eligibility Criteria:
Inclusion Criteria:

* Third year medical student completing family medicine clerkship Uniformed Services University

Exclusion Criteria:

* All students other than those listed above
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA. Eligible patients will receive monthly subcutaneous injections at an initial recommended dose of 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, \>=18 years of age;
* chronic renal anemia;
* no ESA therapy during previous 3 months;
* adequate iron status;
* rapid chronic kidney disease progression.

Exclusion Criteria:

* transfusion of red blood cells during previous 2 months;
* poorly controlled hypertension requiring hospitalization in previous 6 months;
* significant acute or chronic bleeding.
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.


Eligibility Criteria:
Inclusion Criteria:

* must understand and sign the informed consent
* must be medically able to undergo ophthalmic surgery for the NT-501 device insertion and possible removal, as well as the testing required.
* diagnosis of glaucoma characterized by (a) clinical evidence of progressive RGC dysfunction and degeneration using both visual field and at least one structural modality; (b) residual visual field preservation including best-corrected visual acuity (BCVA) better than 20/100; (c) failure to contain glaucomatous progression with maximally tolerated reduction of intraocular pressure (IOP), OR visual field defect affecting fixation, but not reducing BCVA below 20/100.

Exclusion Criteria:

* other corneal, lens, optic nerve or retinal disease causing vision loss,
* blind in one eye
* requirement of acyclovir and/or related products during study
* receiving systemic steroids or other immunosuppressive medications.
* pregnant or lactating.
* considered immunodeficient or has a known history of human immunodeficiency virus (HIV)
* on chemotherapy, or a history of malignancy, UNLESS it was treated successfully 2 years prior to inclusion in the trial.
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer

The study is QL1101-002 additional research, by detecting the blood circulating endothelial cells and blood perfusion parameters change within tumors early prediction efficacy and drug resistance.

Eligibility Criteria:
Inclusion Criteria:

* Aged ≥18 years and ≤75 years;
* Patients with histologically or cytologically confirmed inoperable locally advanced (Stage IIIb, not suitable for multidisciplinary treatment), metastatic (Stage IV), or relapsed non-squamous cell non-small cell lung cancer. Diagnostic result of non-squamous cell non-small cell lung cancer obtained based on sputum cytology should be immunohistochemically confirmed. If a variety of tumor ingredients are mixed, the main cell types should be classified;
* ECOG score of 0-1 points;
* At least one measurable lesion can be evaluated according to RECIST1.1 criteria;
* Patients who have not received systemic anti-tumor therapy of locally advanced or metastatic non-squamous non-small cell lung cancer (if the subject received adjuvant therapy after completing the radical treatment of early non-small cell lung cancer, but then the disease relapsed, the subject can be enrolled. In this case, the end time of the adjuvant therapy is required to be more than 6 months from the time of the first administration of this study, and various toxic reactions resulting from the adjuvant therapy should have recovered (≤ Grade 1 by CTCAE 4.03 criteria, except for alopecia);
* Expected survival time ≥24 weeks;

Exclusion Criteria:

* Central squamous cell carcinoma, and mixed gland squamous cell carcinoma with squamous cell as the main ingredient;
* ALK fusion gene is known to be positive;
* Medical history or examination shows thrombotic disease within 6 months prior to screening;
* Imaging shows signs of tumor invasion of large vessels, and the investigator or radiologist must exclude patients whose tumor has been completely close to or surrounded or invaded the lumen of large vessels (e.g., the superior pulmonary artery or superior vena cava);
* Patients with a past history of symptomatic brain metastases or meningeal metastases, or spinal cord compression;
* Patients who received palliative radiotherapy for bone lesions outside the chest within 2 weeks prior to the first dose of the study drug;
* Patients who received major surgical procedures (including thoracotomy), or suffered from major trauma (such as fractures) within 28 days
* prior to screening, or need to undergo major surgery during the expected study treatment period;
* Patients who received a minor surgical procedure within 48 hours prior to the first treatment with Anivitis® QL1101 (the investigator judges whether there is bleeding tendency);
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

RATIONALE: Genistein may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase II trial to study the effectiveness of genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy.

OBJECTIVES:

* Determine the toxicity of genistein in patients with localized prostate cancer treated with radical prostatectomy.
* Determine the decrease, if any, of prostate-specific antigen-positive cells in the operative field of patients treated with this drug.
* Determine the quality of life of patients treated with this drug.

OUTLINE: Patients receive 1 of 2 treatment regimens.

* Group A: Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
* Group B: Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.

Quality of life is assessed at baseline and at 1 and 3 months after surgery.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 88 patients (44 patients per treatment group) will be accrued for this study within 2 years.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Diagnosis of localized prostate cancer

  * Diagnosed within the past 6 months
  * T1 or T2 disease
  * Gleason score 5-8
  * Prostate-specific antigen no greater than 20 ng/mL
* Radical prostatectomy planned

PATIENT CHARACTERISTICS:

Age

* 18 and over

Performance status

* ECOG 0-1

Life expectancy

* More than 2 years

Hematopoietic

* Hemoglobin greater than 9.0 g/dL
* Platelet count greater than 100,000/mm\^3
* Absolute neutrophil count greater than 1,000/mm\^3

Hepatic

* SGPT and SGOT less than 3 times normal
* Bilirubin less than 3 mg/dL (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)

Renal

* Creatinine less than 2.0 mg/dL

Cardiovascular

* No venous thrombosis within the past year

Other

* Patients must use effective barrier contraception
* No other medical condition that would preclude study therapy
* No known soy intolerance

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* No concurrent hormonal therapy for prostate cancer

Radiotherapy

* Not specified

Surgery

* See Disease Characteristics

Other

* No concurrent soy supplements
* No concurrent foods high in genistein
* No concurrent active therapy for neoplastic disorders
Impact of Covid-19 on Training for ENT and Cervico-Facial Surgery Residents in France

The impact of the Covid-19 pandemic on medical education is real but little known.

ENT interns were directly affected by the management of Covid-19 patients (performing surgical tracheostomies), many conferences and trainings were cancelled, their usual hospital activity deeply reshuffled.

Although each student has a personal story of the impact of Covid-19 on their training, there is no doubt that the effects of Covid-19 are felt at scale. This study aims to investigate the effect of the pandemic on the medical and surgical training of ENT and Cervico-Facial Surgery interns in France from November 2019 to May 2021 (Auvergne-Rhône-Alpes, Grand Est, Ile de France, Nouvelle Aquitaine and Provence-Alpes-Côte d'Azur areas). A questionnaire will be sent by mail to ENT interns in France to assess the impact of Covid-19 on the training of ENT interns in France.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* ENT residents in France (Auvergne-Rhône-Alpes, Grand Est, Ile de France, Nouvelle Aquitaine and Provence-Alpes-Côte d'Azur regions) during the period from November 2019 to May 2021.
* Informed of the objectives of the research and not objecting to the processing of their data

Exclusion Criteria:

- Subjects in research year, on availability, or in off-track training
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Phase 1

* To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
* To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2

Phase 2

• To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2

Phase 3

* Cohort 1 (≥18 Years Old, Not Pregnant at Randomization)

  • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo as measured by COVID-19-related hospitalizations or all-cause death
* Cohort 2 (\<18 Years Old, Not Pregnant at Randomization)

  * To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo
  * To further characterize the concentrations of REGN10933 and REGN10987 in serum over time
* Cohort 3 (Pregnant at Randomization) • To evaluate the safety and tolerability of REGN10933+REGN10987


Eligibility Criteria:
Key Inclusion Criteria:

* Has SARS-CoV-2-positive diagnostic test (from a sample collected ≤72 hours prior to randomization, using a validated SARS-CoV-2 antigen, RT-PCR, or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal \[NP\], nasal, oropharyngeal \[OP\], or saliva)
* Has symptoms consistent with COVID-19, as determined by the investigator, with onset ≤7 days before randomization
* Maintains O2 saturation ≥93% on room air
* Is able to understand and complete study-related questionnaires (patients aged ≥12 years only)

Key Exclusion Criteria:

* Was admitted to a hospital for COVID-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization
* Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, mAbs against SARS-CoV-2 (eg, bamlanivimab), or intravenous immunoglobulin (IVIG) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit
* Prior, current, or planned future use of any of the following treatments: COVID-19 convalescent plasma, mAbs against SARS-CoV-2 (eg, bamlanivimab), IVIG (any indication), systemic corticosteroids (any indication), or COVID-19 treatments (authorized, approved, or investigational)
* Prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current CDC recommendations, as applicable) of any authorized or approved vaccine for COVID-19
* Has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for COVID-19

NOTE: Other Protocol defined Inclusion/Exclusion criteria apply
Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones

In patients with gallbladder in situ after complete removal of common bile duct (CBD) stones, there is no definite guideline for the management of remnant acalculous gallbladder. This study was planned to evaluate the efficacy of choleretic agents in those patients comparing with non-treatment group during short (2 years) and long-term (5 to 10 years) period. So that, the investigators want to establish the treatment guideline in gallbladder in situ without definite stones following complete removal of CBD stones. Second, the protective or preventive effect of choleretics may be defined.


Eligibility Criteria:
Inclusion Criteria:

* Complete clearance of CBD stones
* No definite GB stones
* Agree with the study protocol

Exclusion Criteria:

* \< 18 years of age
* Concomitant IHD stones
* Combined malignancy with a limted life span
* Prior cholecystectomy state
* refusal to agree to the study protocol
Study on Brain Function of Obesity Classification

The purpose of this study was to investigate the differences and similarities of brain function in patients with four subtypes of obesity, and the relationship between brain function changes and complications after weight loss and metabolic improvement. 120 patients with obesity and 30 healthy individuals with normal BMI were enrolled.

Although the investigators have clinically observed significant differences in appetite and metabolic status in patients with the above four types of obesity, the brain functional characteristics of different obesity subtypes and their relationship with metabolic markers are still unclear. Based on this, in this project, the investigators plan to explore further the similarities and differences in brain function in patients with four subtypes of obesity and the relationship between brain function changes after weight loss and metabolic improvement and the occurrence of complications.

120 patients with obesity and 30 healthy individuals with normal BMI were enrolled.

All patients with obesity underwent LSG. A multidisciplinary team evaluated participants with obesity at baseline, 1, 3, 6, and 12 months after laparoscopic sleeve gastrectomy (LSG). Anthropometrics, Metabolic indicators, sex hormones, menstruation，glucose-lipid metabolic markers, and hepatic steatosis assessed by FibroScan(CAP value and E value) were measured baseline and postoperative. Resting and task state functional magnetic resonance imaging (fMRI) measurements were performed at baseline for all participants at two-time points before and after meals. Measurements were repeated in obese patients 6 months after surgery.

Eligibility Criteria:
Inclusion Criteria:

* age ranged from 16-65 years old
* BMI over 37.5kg/m2, or BMI over 32.5kg/m2 with diabetes which meets the recommended cut-off bariatric surgery of the Guidelines for surgical treatment of obesity accompanied with or without type 2 diabetes in China.

Exclusion Criteria:

* secondary causes of obesity such as hypothalamic obesity, Cushing syndrome, hypophysis dysfunction, etc
* pregnancy or location
* contraindications for laparoscopic surgery, such as gastrointestinal diseases of intra-abdominal infection, adhesion, etc
* severe heart, liver, and kidney dysfunction
* organic and systemic diseases intolerant of surgery.
Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor

The purpose of this study is to evaluate the efficacy of stereotactic lung radiation therapy after concomitant radiochemotherapy for unresectable stage III non-small cell lung carcinoma (NSCLC) with peripheral primary tumor.

Evaluate in terms of local control rate at 6 months the addition of stereotactic radiotherapy after concurrent chemoradiotherapy in the treatment of mediastinal non-resectable stage III NSCLC having a peripheral primary tumor.

The number of patients required in this multicenter prospective study is 70.

This is a prospective, multicenter, non comparative and non randomized study.

Stereotactic radiotherapy or SBRT (Body Stereotactic Radiation Therapy) allows to irradiate with high dose limited lesions size with a local control surrounding of 80-98% and with a low level of toxicity.

We propose to realize a classic concomitant RT-CT for mediastinal irradiation and combine this treatment with stereotactic RT for peripheral primary tumor.

The estimated inclusion period is approximately 3 years.

Follow-up duration for each patient is 2 years. The duration of the research is 5 years.

Eligibility Criteria:
Inclusion Criteria:

* 18 years ≤ Age ≤ 75 years
* PS ECOG 0 or 1
* Histologically proven NSCLC
* Unresectable stage III: T1 or T2 or T3 ≤ 5 cm AND N2 or N3 (only contralateral mediastinum or homolateral supraclavicular).
* Peripheral primary tumor ≥ 1 cm and ≤ 5 cm
* Possible concomitant chemoradiotherapy : 1 cure induction and 3 concomitant cycles of chemotherapy with cisplatin and Navelbine ® and 3D conformal radiotherapy delivering 66 Gy in 33 fractions to the mediastinal lymph node involvement without treating the peripheral tumor.
* Adequate biological parameters
* Forced expiratory volume (FEV) ≥1 liter or ≥ 30% of the theoretical value
* Patient covered by a health insurance scheme
* Signed informed consent

Exclusion Criteria:

* SCLC or large cell neuroendocrine carcinoma
* Metastatic disease
* Stage IVa
* Pregnant or breast-feeding women
Dietary Protein Requirement of Elderly Men and Women

The purpose of this study was to assess the effect of age on the estimated average requirement and adequate allowance for dietary protein.


Eligibility Criteria:
Inclusion Criteria:

* Age: 21-46 years, 63-81 years old
* Not diagnosed with diabetes or metabolic syndrome
* Clinically normal blood laboratory values

Exclusion Criteria:

* Age: 21 years of younger, 47-62 years old, and 82 years and older
* BMI: 20-29 kg/m
* Weight stable: \<2kg change within the last 3 months
* Physical Activity: constant habitual pattern, no deviation \>1x week of 30/minute sessions within the last 3 months

Clinically abnormal values:

* Blood
* Urine

Also, exclude any:

* Using meds that would influence appetite
* Using any anti-inflammatory steroid medications
* Has a joint replacement
* A medical condition that might place them at risk for participating in the study or interfere with successful completion of the study